Other News To Note

• Amicus Therapeutics Inc., of Cranbury, N.J., received a two-year, $186,000 grant from the Muscular Dystrophy Association (MDA) to evaluate the effect of the pharmacological chaperone AT2220 (duvoglustat HCl) on immunogenicity related to the enzyme replacement therapy (ERT) alglucosidase alfa, the only approved treatment for Pompe disease. As part of the MDA grant, Amicus will investigate the ability of AT2220 to mitigate ERT-specific immunogenicity from blood samples obtained in the ongoing open-label Phase II drug-drug interaction study of AT2220 co-administered with ERT in individuals with Pompe disease and from normal donors.